Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo
nivolumab · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory classical Hodgkin lymphoma after autologous stem-cell transplant and brentuximab vedotin.
LAMPGEN ANALYSIS
Why it matters
This converts a previously accelerated post-transplant indication to traditional approval. The first-line AVD decision announced the same day is a distinct use.
What research teams should watch
Capture the transplant and brentuximab treatment sequence before assigning the approved use. Cite the conversion evidence separately from first-line SWOG 1826 results.
PRIMARY RECORDS